Muscle-specific vascular endothelial growth factor deletion induces muscle capillary rarefaction creating muscle insulin resistance

Jeffrey S Bonner, Louise Lantier, Clinton M Hasenour, Freyja D James, Deanna P Bracy, David H Wasserman, Jeffrey S Bonner, Louise Lantier, Clinton M Hasenour, Freyja D James, Deanna P Bracy, David H Wasserman

Abstract

Muscle insulin resistance is associated with a reduction in vascular endothelial growth factor (VEGF) action and muscle capillary density. We tested the hypothesis that muscle capillary rarefaction critically contributes to the etiology of muscle insulin resistance in chow-fed mice with skeletal and cardiac muscle VEGF deletion (mVEGF(-/-)) and wild-type littermates (mVEGF(+/+)) on a C57BL/6 background. The mVEGF(-/-) mice had an ~60% and ~50% decrease in capillaries in skeletal and cardiac muscle, respectively. The mVEGF(-/-) mice had augmented fasting glucose turnover. Insulin-stimulated whole-body glucose disappearance was blunted in mVEGF(-/-) mice. The reduced peripheral glucose utilization during insulin stimulation was due to diminished in vivo cardiac and skeletal muscle insulin action and signaling. The decreased insulin-stimulated muscle glucose uptake was independent of defects in insulin action at the myocyte, suggesting that the impairment in insulin-stimulated muscle glucose uptake was due to poor muscle perfusion. The deletion of VEGF in cardiac muscle did not affect cardiac output. These studies emphasize the importance for novel therapeutic approaches that target the vasculature in the treatment of insulin-resistant muscle.

Figures

FIG. 1.
FIG. 1.
VEGF-A protein levels in tissue homogenates from cardiac and skeletal muscle (A) and VEGF-A plasma concentration (B). Skeletal muscle VEGF levels were quantified in the gastrocnemius. Values are expressed as means ± SE (n = 5). *P ≤ 0.05 vs. mVEGF+/+.
FIG. 2.
FIG. 2.
Arterial glucose (A) and glucose infusion rate (B) during the hyperinsulinemic-euglycemic clamp. Mice were fasted 5 h before the onset of the clamp. Blood glucose was maintained at ∼150 mg/dL during steady-state (80–120 min), and the time course is displayed to demonstrate quality of the clamp. Glucose (50%) was infused to maintain euglycemia. EndoRa (C), whole-body Rd, (D), and insulin-stimulated glucose disposal (E) were determined during the hyperinsulinemic-euglycemic clamp. Basal values were determined from samples at −15 and −5 min before the onset of the clamp, and insulin clamp levels were calculated from steady-state values (80–120 min). Insulin-stimulated Rd was calculated by subtracting the basal Rd from the clamp Rd, which measures the increase in insulin-stimulated glucose disposal. Data are expressed as mean ± SE (n = 7–9). *P ≤ 0.05 vs. mVEGF+/+.
FIG. 3.
FIG. 3.
Glucose tolerance was determined (A), and corresponding plasma insulin levels were quantified (B) on 5-h fasted mice. C: The area under the curve was determined from 0 to 30 min and normalized to fasting arterial glucose concentration. D: RT-PCR was performed on hepatic RNA extracts from mice fasted for 5 h for the relative expression of the gluconeogenic genes PEPCK and G6Pase. Values are expressed as mean ± SE (n = 5–6). *P ≤ 0.05 vs. mVEGF+/+.
FIG. 4.
FIG. 4.
Insulin-stimulated Rg in skeletal (A) and cardiac (B) muscle. To quantify insulin-stimulated Rg, we performed a time control in a cohort of mVEGF+/+ and mVEGF−/− mice in which saline was infused in lieu of insulin to quantify basal Rg. The Rg values from the saline infusion were averaged and subtracted from the Rg values during the insulin clamp. Data are expressed as mean ± SE (n = 7–9). *P ≤ 0.05 vs. mVEGF+/+.
FIG. 5.
FIG. 5.
Skeletal muscle and hepatic insulin signaling after the hyperinsulinemic-euglycemic clamp. Western blot analysis was performed on extracts of the gastrocnemius and liver for the phosphorylation (p) of Akt at Ser473 and total Akt. Infrared imaging was performed on 4–12% SDS-PAGE gel in skeletal muscle (A and C) and liver (E). A: Immunoprecipitation (IP) from gastrocnemius extracts were performed with total IRS-1; then, immunoblots (IB) were completed for p-IRS-1 at Tyr612 and the p85 subunit of PI3K. B: Insulin-stimulated p85 association with p-IRS-1 was quantified as the ratio of p85–to–p-IRS-1. Insulin activation of Akt (C and E) was quantified as the ratio of p-Akt to total Akt in skeletal muscle (D) and liver (F). GAPDH was used as a loading control. Data are expressed as mean ± SE (n = 5–6). *P ≤ 0.05 vs. mVEGF+/+.
FIG. 6.
FIG. 6.
Skeletal muscle insulin action was assessed in the isolated soleus (A) and extensor digitorum longus (B). Mice were fasted for 5 h before the excision of the muscles. Values are expressed as mean ± SE (n = 6).

References

    1. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173–194
    1. Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 2003;285:E123–E129
    1. Fueger PT, Shearer J, Bracy DP, et al. Control of muscle glucose uptake: test of the rate-limiting step paradigm in conscious, unrestrained mice. J Physiol 2005;562:925–935
    1. Halseth AE, Bracy DP, Wasserman DH. Limitations to basal and insulin-stimulated skeletal muscle glucose uptake in the high-fat-fed rat. Am J Physiol Endocrinol Metab 2000;279:E1064–E1071
    1. Chiu JD, Richey JM, Harrison LN, et al. Direct administration of insulin into skeletal muscle reveals that the transport of insulin across the capillary endothelium limits the time course of insulin to activate glucose disposal. Diabetes 2008;57:828–835
    1. Ellmerer M, Hamilton-Wessler M, Kim SP, et al. Reduced access to insulin-sensitive tissues in dogs with obesity secondary to increased fat intake. Diabetes 2006;55:1769–1775
    1. Kang L, Ayala JE, Lee-Young RS, et al. Diet-induced muscle insulin resistance is associated with extracellular matrix remodeling and interaction with integrin alpha2beta1 in mice. Diabetes 2011;60:416–426
    1. Frisbee JC. Hypertension-independent microvascular rarefaction in the obese Zucker rat model of the metabolic syndrome. Microcirculation 2005;12:383–392
    1. Guo Q, Mori T, Jiang Y, et al. Losartan modulates muscular capillary density and reverses thiazide diuretic-exacerbated insulin resistance in fructose-fed rats. Hypertens Res 2012;35:48–54
    1. Berria R, Wang L, Richardson DK, et al. Increased collagen content in insulin-resistant skeletal muscle. Am J Physiol Endocrinol Metab 2006;290:E560–E565
    1. Solomon TP, Haus JM, Li Y, Kirwan JP. Progressive hyperglycemia across the glucose tolerance continuum in older obese adults is related to skeletal muscle capillarization and nitric oxide bioavailability. J Clin Endocrinol Metab 2011;96:1377–1384
    1. Vincent MA, Clerk LH, Lindner JR, et al. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004;53:1418–1423
    1. Baron AD, Laakso M, Brechtel G, Edelman SV. Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab 1991;73:637–643
    1. Baron AD, Tarshoby M, Hook G, et al. Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. Diabetes 2000;49:768–774
    1. Kim F, Pham M, Maloney E, Rizzo NO, Morton GJ, Wisse BE, Kirk EA, Chait A, Schwartz MW. Vascular inflammation, insulin resistance, and reduced nitric oxide production precedes the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 2008;28:1982–1988
    1. Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011;13:294–307
    1. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990;85:1844–1852
    1. Gavin TP, Stallings HW, 3rd, Zwetsloot KA, et al. Lower capillary density but no difference in VEGF expression in obese vs. lean young skeletal muscle in humans. J Appl Physiol 2005;98:315–321
    1. Lillioja S, Young AA, Culter CL, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987;80:415–424
    1. Mårin P, Andersson B, Krotkiewski M, Björntorp P. Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care 1994;17:382–386
    1. Chung AW, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 2006;99:140–148
    1. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007;56:1025–1033
    1. Chai W, Wang W, Dong Z, Cao W, Liu Z. Angiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivo. Diabetes 2011;60:2939–2946
    1. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359–371
    1. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002;105:373–379
    1. Sasso FC, Torella D, Carbonara O, et al. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 2005;46:827–834
    1. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 2007;101:948–956
    1. Olfert IM, Howlett RA, Tang K, et al. Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice. J Physiol 2009;587:1755–1767
    1. Tang K, Breen EC, Gerber HP, Ferrara NMA, Wagner PD. Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. Physiol Genomics 2004;18:63–69
    1. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149–1159
    1. Berglund ED, Li CY, Poffenberger G, et al. Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 2008;57:1790–1799
    1. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 2006;55:390–397
    1. Jornayvaz FR, Birkenfeld AL, Jurczak MJ, et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc Natl Acad Sci U S A 2011;108:5748–5752
    1. Kim HJ, Higashimori T, Park SY, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004;53:1060–1067
    1. Steele R, Wall JS, De Bodo RC, Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 1956;187:15–24
    1. Chan TM, Exton JH. A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem 1976;71:96–105
    1. Golden S, Wals PA, Katz J. An improved procedure for the assay of glycogen synthase and phosphorylase in rat liver homogenates. Anal Biochem 1977;77:436–445
    1. Jørgensen SB, Viollet B, Andreelli F, et al. Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle.. J Biol Chem 2004;279:1070–1079
    1. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
    1. Arsic N, Zacchigna S, Zentilin L, et al. Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol Ther 2004;10:844–854
    1. Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 1999;104:733–741
    1. Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab 2011;301:E252–E263
    1. Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes 2006;55:1436–1442
    1. Sjöstrand M, Gudbjörnsdottir S, Holmäng A, Lönn L, Strindberg L, Lönnroth P. Delayed transcapillary transport of insulin to muscle interstitial fluid in obese subjects. Diabetes 2002;51:2742–2748
    1. Lindbom L. Microvascular blood flow distribution in skeletal muscle. An intravital microscopic study in the rabbit. Acta Physiol Scand Suppl 1983;525:1–40
    1. Honig CR, Odoroff CL, Frierson JL. Active and passive capillary control in red muscle at rest and in exercise. Am J Physiol 1982;243:H196–H206
    1. de Jongh RT, Clark AD, IJzerman RG, Serné EH, de Vries G, Stehouwer CD. Physiological hyperinsulinaemia increases intramuscular microvascular reactive hyperaemia and vasomotion in healthy volunteers. Diabetologia 2004;47:978–986
    1. Trask RV, Billadello JJ. Tissue-specific distribution and developmental regulation of M and B creatine kinase mRNAs. Biochim Biophys Acta 1990;1049:182–188
    1. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435–439
    1. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439–442
    1. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691–703
    1. Ruhrberg C, Gerhardt H, Golding M, et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002;16:2684–2698
    1. Giordano FJ, Gerber HP, Williams SP, et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 2001;98:5780–5785
    1. Yoon YS, Uchida S, Masuo O, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005;111:2073–2085
    1. Goldstein RE, Wasserman DH, McGuinness OP, Lacy DB, Cherrington AD, Abumrad NN. Effects of chronic elevation in plasma cortisol on hepatic carbohydrate metabolism. Am J Physiol 1993;264:E119–E127
    1. Gudbjörnsdóttir S, Sjöstrand M, Strindberg L, Lönnroth P. Decreased muscle capillary permeability surface area in type 2 diabetic subjects. J Clin Endocrinol Metab 2005;90:1078–1082

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren